What the FDA labels say about taking them together
Lurasidone and voriconazole
Lurasidone's FDA label of January 31, 2025 names voriconazole in its contraindications section, and voriconazole's label names lurasidone too. The voriconazole label: “Contraindicated”
Check it at the source: the lurasidone FDA label on DailyMed (effective January 31, 2025, Sumitomo Pharma America, Inc.); the voriconazole FDA label on DailyMed (effective February 26, 2026, Roerig).
What does the lurasidone label say about voriconazole?
Lurasidone label, contraindicationsStrong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil, etc.) [see Drug Interactions ( 7.1 )].
Lurasidone label, drug interactionsStrong CYP3A4 Inhibitors Clinical Impact: Concomitant use of LATUDA with strong CYP3A4 inhibitors increased the exposure of lurasidone compared to the use of LATUDA alone. Intervention: LATUDA should not be used concomitantly with strong CYP3A4 inhibitors [see Contraindications ()]. Examples: Ketoconazole, clarithromycin, ritonavir, voriconazole, mibefradil
Source: FDA drug label (Latuda), NDA200603 (Sunovion Pharms Inc), as published by Sumitomo Pharma America, Inc., effective January 31, 2025 (SPL set afad3051-9df2-4c54-9684-e8262a133af8), via openFDA; the full label on DailyMed
What does the voriconazole label say about lurasidone?
Voriconazole label, drug interactionsDrug/Drug Class (Mechanism of Interaction by Voriconazole): Lurasidone (CYP3A4 Inhibition); Drug Plasma Exposure (C max and AUC τ): Not Studied In Vivo or In Vitro, but Voriconazole is Likely to Significantly Increase the Plasma Concentrations of Lurasidone; Prevention or Management Recommendations: Contraindicated
Voriconazole label (Xellia Pharmaceuticals USA LLC, January 11, 2023), contraindicationsCoadministration of Voriconazole for injection with lurasidone is contraindicated since it may result in significant increases in lurasidone exposure and the potential for serious adverse reactions [see Drug Interactions (7) ].
Voriconazole label (Xellia Pharmaceuticals USA LLC, January 11, 2023), drug interactionsDrug/Drug Class (Mechanism of Interaction by Voriconazole): Lurasidone (CYP3A4 Inhibition); Drug Plasma Exposure (C max and AUC τ): Not Studied In Vivo or In Vitro, but Voriconazole is Likely to Significantly Increase the Plasma Concentrations of Lurasidone; Recommendations for Drug Dosage Adjustment/Comments: Contraindicated
Source: FDA drug label (Voriconazole, NDA208562), Xellia Pharmaceuticals USA LLC, effective January 11, 2023 (SPL set 9ec6eda2-2f15-423b-9ec6-819379a426e1), via openFDA
Source: FDA drug label (VFEND), NDA021630 (Pf Prism Cv), as published by Roerig, effective February 26, 2026 (SPL set ce3ef5cf-3087-4d92-9d94-9eb8287228db), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Lurasidone | Voriconazole | |
|---|---|---|
| Labeled for | Schizophrenia, Bipolar disorder, Depression | Fungal infections |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $0.142 per tablet 20 mg tablet | $1.88 per tablet 200 mg tablet |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once